... M.D., FRCPC, Texas Oncology – San Antonio Medical Center and a Principal Investigator on IDEAYA's Phase 1/2 clinical trial.
News
- IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple ...
- Why NGM Biopharmaceuticals' stock fell more than 70% - San Francisco Business Times
... Providence Raleigh/Durham Sacramento San Antonio San Francisco Seattle ... Why star-studded Peninsula biotech NGM Biopharmaceuticals saw its ...
- President's Forum 2022: Large investments for huge impacts - UT Health San Antonio
William L. Henrich, MD, MACP, president of UT Health San Antonio, ... including new buildings for biomedical research, the Center for Brain Health ...
- Struggling blood disorder biotech shuts down via reverse merger - The Business Journals
... will be no more following a reverse merger with a Colorado biotech. ... Providence Raleigh/Durham Sacramento San Antonio San Francisco Seattle ...
- TAMIU announces over $3.5M in grants - mySA
Decked-out entertainment center to bowl over San Antonio ... “For the TAMIU students who are intending to pursue a career in biomedical sciences, ...